Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The mechanism by which mutations in the presenilin (PS) genes cause the most aggressive form of early-onset Alzheimer's disease (AD) is unknown, but fibroblasts from mutation carriers secrete increased levels of the amyloidogenic A beta 42 peptide, the main component of AD plaques. We established transfected cell and transgenic mouse models that coexpress human PS and amyloid beta-protein precursor (APP) genes and analyzed quantitatively the effects of PS expression on APP processing. In both models, expression of wild-type PS genes did not alter APP levels, alpha- and beta-secretase activity and A beta production. In the transfected cells, PS1 and PS2 mutations caused a highly significant increase in A beta 42 secretion in all mutant clones. Likewise, mutant but not wildtype PS1 transgenic mice showed significant overproduction of A beta 42 in the brain, and this effect was detectable as early as 2-4 months of age. Different PS mutations had differential effects on A beta generation. The extent of A beta 42 increase did not correlate with presenilin expression levels. Our data demonstrate that the presenilin mutations cause a dominant gain of function and may induce AD by enhancing A beta 42 production, thus promoting cerebral beta-amyloidosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous studies have shown that mice coexpressing FAD mutant APP and PS1 transgenes exhibit additive increases in A 𝛃 42 production (Borchelt et al., 1996, 1997; Citron et al., 1997; Holcomb et al., 1998), althoughrarely have more than two A 𝛃 42 -elevating FAD mutations been combined in transgenic animals.”
From Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation (2006) · cites this paper as Citron et al., 1997
In the citing paper
“each of these genetic forms of AD either selectively increases the extracellular concentration of A42 (Suzuki et al., 1994;Borchelt et al., 1996;Duff et al., 1996;Scheuner et al., 1996;Citron et al., 1997) or increases both A42 and A40 (Cai et al., 1993;Citron et al., 1994;Scheuner et al., 1996).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Citron et al., 1997
In the citing paper
“familial EOAD mutations in PSEN1 and PSEN2 typically result in an increased production of longer and more aggregation-prone derivatives of APP such as Aβ1–42 [47–49].”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [47]
Citations
Cites
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationScheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Self-citationRogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Self-citationJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Self-citationEndoproteolysis of Presenilin 1 and Accumulation of Processed Derivatives In Vivo
Thinakaran, G., Borchelt, D. R., Lee, M. K., Slunt, H. H., Spitzer, L., Kim, G., Ratovitsky, T., Davenport, F., Nordstedt, C., Seeger, M., et al. (1996) · Neuron · doi:10.1016/s0896-6273(00)80291-3 · Cited by 1,013
Self-citationPrusiner, S. B., Scott, M., Foster, D., Pan, K.-M., Groth, D., Mirenda, C., Torchia, M., Yang, S.-L., Serban, D., Carlson, G. A., et al. (1990) · Cell · doi:10.1016/0092-8674(90)90134-z · Cited by 871
Self-citationAmyloid β-Protein and the Genetics of Alzheimer's Disease
Selkoe, D. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.31.18295 · Cited by 799
Self-citationRadzicka, A., & Wolfenden, R. (1988) · Biochemistry · doi:10.1021/bi00405a042 · Cited by 606
Cited by
Items 701–800 of 1,002
Karlnoski, R. A., Rosenthal, A., Kobayashi, D., Pons, J., Alamed, J., Mercer, M., Li, Q., Gordon, M. N., Gottschall, P. E., & Morgan, D. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4560-08.2009 · Cited by 34
“, 1994), and genetic evidence in vivo shows increased levels of A 42 predisposes for disease (Mann et al., 1996; Citron et al., 1997).”
BackgroundMitochondrial mechanisms in amyloid beta peptide-induced cerebrovascular degeneration
Hsu, M., Sheu, J., Lin, C., Shen, M., & Hsu, C. Y. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.08.003 · Cited by 39
Kuwabara, Y., Ishizeki, M., Watamura, N., Toba, J., Yoshii, A., Inoue, T., & Ohshima, T. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12728 · Cited by 36
“Mutations in presenilin 1 (PS1) and PS2 are considered to enhance susceptibility to late-onset AD (Duff et al. 1996; Citron et al. 1997).”
BackgroundRescue of Transgenic Alzheimer’s Pathophysiology by Polymeric Cellular Prion Protein Antagonists
Gunther, E. C., Smith, L. M., Kostylev, M. A., Cox, T. O., Kaufman, A. C., Lee, S., Folta-Stogniew, E., Maynard, G. D., Um, J. W., Stagi, M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.021 · Cited by 35
Huang, X., Yee, B. K., Nag, S., Chan, S. T. H., & Tang, F. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00242-5 · Cited by 36
Jacobsen, H., Reinhardt, D., Brockhaus, M., Bur, D., Kocyba, C., Kurt, H., Grim, M. G., Baumeister, R., & Loetscher, H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.49.35233 · Cited by 34
Inhibitors of β-Amyloid Formation Based on the β-Secretase Cleavage Site
Abbenante, G., Kovacs, D. M., Leung, D., Craik, D. J., Tanzi, R. E., & Fairlie, D. P. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2098 · Cited by 37
An Alzheimer's disease hypothesis based on transcriptional dysregulation
Robakis, N. K. (2003) · Amyloid · doi:10.3109/13506120309041729 · Cited by 35
Liu, B., Wang, L., Shen, L., Shen, M., Guo, X., Wang, T., Liang, Q., Wang, C., Zheng, J., Li, Y., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos138 · Cited by 33
“PS2 and PS1 are highly homologous transmembrane proteins, and 2 of their main roles in cellular functions are to increase the production of the amyloidogenic Ab peptide and to regulate Notch signaling.(15,16) However, the distinctly different phenotypes of PS1-deficient and PS2-deficient mice suggest that these protei…”
BackgroundExcitatory synaptic transmission is depressed in cultured hippocampal neurons of APP/PS1 mice
Priller, C., Mitteregger, G., Paluch, S., Vassallo, N., Staufenbiel, M., Kretzschmar, H. A., Jucker, M., & Herms, J. W. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.10.016 · Cited by 38
Genetic variants associated with neurodegenerative Alzheimer disease in natural models
Salazar, C., Valdivia, G., Ardiles, Á. O., Ewer, J., & Palacios, A. G. (2016) · Biological Research · doi:10.1186/s40659-016-0072-9 · Cited by 36
“Presenilins are catalytic proteins of γ-secretase complexes responsible for producing Aβ from APP [52]; thus, mutations in PSEN1 and PSEN2 affect the generation of Aβ peptide [13, 22, 27, 35, 40, 95].”
BackgroundEnhanced accumulation of tau in doubly transgenic mice expressing mutant βAPP and presenilin-1
Samura, E., Shoji, M., Kawarabayashi, T., Sasaki, A., Matsubara, E., Murakami, T., Wuhua, X., Tamura, S., Ikeda, M., Ishiguro, K., et al. (2006) · Brain Research · doi:10.1016/j.brainres.2005.12.134 · Cited by 37
Self-citationTaddei, K., Fisher, C., Laws, S. M., Martins, G., Paton, A., Clarnette, R., Chung, C., Brooks, W. S., Hallmayer, J. F., Miklossy, J., et al. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001072 · Cited by 36
Okochi, M., Ishii, K., Usami, M., Sahara, N., Kametani, F., Tanaka, K., Fraser, P. E., Ikeda, M., Saunders, A. M., Hendriks, L., et al. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01378-1 · Cited by 33
Self-citationHui, J., Feng, G., Zheng, C., Jin, H. M., & Jia, N. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.10.030 · Cited by 36
Overview on Rodent Models of Alzheimer's Disease
Dodart, J., & May, P. (2005) · Current Protocols in Neuroscience · doi:10.1002/0471142301.ns0922s33 · Cited by 32
“By contrast, tg mice expressing either a wt or mutated PS gene fail to develop significant AD-like pathology (Borchelt et al., 1996; Duff et al., 1996; Citron et al., 1997; Oyama et al., 1998; Chui et al., 1999).”
BackgroundProtein markers for Alzheimer disease in the frontal cortex and cerebellum
Verdile, G., Gnjec, A., Miklossy, J., Fonte, J., Veurink, G., Bates, K., Kakulas, B., Mehta, P. D., Milward, E. A., Tan, N., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000141848.45315.a6 · Cited by 32
What Can Rodent Models Tell Us About Cognitive Decline in Alzheimer's Disease?
Davis, S., & Laroche, S. (2003) · Molecular Neurobiology · doi:10.1385/mn:27:3:249 · Cited by 38
Screening for Presenilin Inhibitors Using the Free-Living Nematode, Caenorhabditis elegans
Ellerbrock, B. R., Coscarelli, E. M., Gurney, M. E., & Geary, T. G. (2004) · SLAS DISCOVERY · doi:10.1177/1087057103261038 · Cited by 32
Biology of presenilins as causative molecules for Alzheimer disease
Nishimura, M., Yu, G., & George‐Hyslop, P. S. (1999) · Clinical Genetics · doi:10.1034/j.1399-0004.1999.550401.x · Cited by 32
Insights into Aβ and Presenilin from a Canine Model of Human Brain Aging
Head, E., & Torp, R. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2002.0476 · Cited by 33
Current neuroimaging techniques in Alzheimer's disease and applications in animal models.
Zhang, L., Chang, R. C., Chu, L., & Mak, H. K. (2012) · Europe PMC (PubMed Central) · Cited by 35
Trambauer, J., Sarmiento, R. M. R., Fukumori, A., Feederle, R., Baumann, K., & Steiner, H. (2019) · EMBO Reports · doi:10.15252/embr.201947996 · Cited by 32
Cerebrospinal fluid Aβ40 and Aβ42: Natural course and clinical usefulness
Shoji, M., & Kanai, M. (2001) · Journal of Alzheimer's Disease · doi:10.3233/jad-2001-3306 · Cited by 31
Prevention of age-associated dementia
Mohajeri, M. H., & Leuba, G. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.06.014 · Cited by 36
Advances in the identification of β-secretase inhibitors
Hamada, Y., & Kiso, Y. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.784267 · Cited by 30
“A breakthrough was made through the genetic study of some familial AD (FAD) patients who were found to have mutations of the gene coding for amyloid precursor protein (APP) and preseniline 1 and 2 genes, and these mutations caused an increase in amyloid b peptides (Ab), which are the main components of senile plaques…”
BackgroundGu, M., & Viles, J. H. (2016) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2016.04.009 · Cited by 34
Anti‐PrPC antibody rescues cognition and synapses in transgenic alzheimer mice
Cox, T. O., Gunther, E. C., Brody, A. H., Chiasseu, M. T., Stoner, A., Smith, L. M., Haas, L. T., Hammersley, J., Rees, G., Dosanjh, B., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.730 · Cited by 33
In search of genes involved in neurodegenerative disorders
Pardo, L. M., & van Duijn, C. M. (2005) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2005.06.006 · Cited by 34
The very many faces of presenilins and the γ-secretase complex
Smolarkiewicz, M., Skrzypczak, T., & Wojtaszek, P. (2013) · PROTOPLASMA · doi:10.1007/s00709-013-0494-y · Cited by 35
“The latter are highly amyloidogenic, and their accumulation leads to plaque formation and progressive neurodegeneration (Citron et al. 1997).”
BackgroundYasuda, M. (2000) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.68.2.220 · Cited by 30
Monogenic determinants of familial Alzheimer's disease: presenilin-1 mutations
Kovacs, D. M., & Tanzi, R. E. (1998) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050219 · Cited by 33
Presenilins, amyloid-β and Alzheimer's disease
Lamb, B. T. (1997) · Nature Medicine · doi:10.1038/nm0197-28 · Cited by 30
Processing of presenilin 1 in brains of patients with Alzheimerʼs disease and controls
Hendriks, L., Thinakaran, G., Harris, C. L., Jonghe, C. D., Martin, J., Sisodia, S. S., & Broeckhoven, C. V. (1997) · Neuroreport · doi:10.1097/00001756-199705060-00030 · Cited by 30
Cellular and molecular basis of beta-amyloid precursor protein metabolism
Xu, H. (1998) · Frontiers in Bioscience · doi:10.2741/a283 · Cited by 2
Johnson, R. D., Steel, D. G., & Gafni, A. (2014) · Protein Science · doi:10.1002/pro.2479 · Cited by 30
A novel presenilin 1 mutation (L174 M) in a large Cuban family with early onset Alzheimer disease
Bertoli‐Avella, A. M., Teruel, B. M., Rodríguez, J. J. L., Viera, N. G., Martinez, I. B., Severijnen, E., Joosse, M., van Duijn, C. M., Baute, L. H., & Heutink, P. (2002) · Neurogenetics · doi:10.1007/s10048-002-0136-6 · Cited by 29
Mehdizadeh, M., Hashem-Dabaghian, F., Shojaee, A., Molavi, N., Taslimi, Z., Shabani, R., & Asl, S. S. (2017) · Basic and Clinical Neuroscience Journal · doi:10.18869/nirp.bcn.8.3.249 · Cited by 29
“Accumulation of Amyloid β (Aβ) in the brain is considered as 1 of the major contributing factors to the development of AD (Citron et al., 1997).”
Nakajima, M., Miura, M., Aosaki, T., & Shirasawa, T. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00478.x · Cited by 30
“In fact, the function of PS1 on the production of the longer form of Ab, Ab42, has been conferred on cells by FAD-linked PS1 mutations (Borchelt et al. 1996; Duff et al. 1996; Citron et al. 1997).”
BackgroundOf mice and men: more neurobiology in dementia
Codita, A., Winblad, B. G., & Mohammed, A. H. (2006) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000245757.06374.6a · Cited by 36
Transforming growth factor β2 autocrinally mediates neuronal cell death induced by amyloid‐β
Hashimoto, Y., Nawa, M., Chiba, T., Aiso, S., Nishimoto, I., & Matsuoka, M. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.20804 · Cited by 29
“…transgenic mice overexpressing FAD genes and mice with V642I mutation in the endogenous APP gene, generated by the knock-in technique (Borchelt et al., 1996; Citron et al., 1997; Janus et al., 2001; Kawasumi et al., 2004), suggesting that toxic Abs are involved in the onset and progression of AD.”
BackgroundLeutz, S., Steiner, B., Marques, C. A., Haass, C., Müller, W. E., & Eckert, A. (2002) · Journal of Molecular Neuroscience · doi:10.1385/jmn:18:3:189 · Cited by 32
“In contrast to APPsw, other FAD-related APP mutations, e.g., V717, or mutations in PS1/2 selectively increase the levels of the longer and more amyloidogenic form Aβ1-42 (Suzuki et al., 1994; Scheuner et al., 1996; Borchelt et al., 1996; Duff et al., 1996; Citron et al., 1997).”
ResultTransgenic Mouse Models of Alzheimer's Disease and Amyotrophic Lateral Sclerosis
Borchelt, D., Wong, P. C., Sisodia, S. S., & Price, D. L. (1998) · Brain Pathology · doi:10.1111/j.1750-3639.1998.tb00198.x · Cited by 30
“Lines of Tg mice that express the G37R Hu SOD1 at 3-12x the level of endogenous SOD1, in the spinal cord, invariably develop MND (Fig.”
InfluentialLocalization and Possible Functions of Presenilins in Brain
McGeer, P. L., Kawamata, T., & McGeer, E. G. (1998) · Reviews in the Neurosciences · doi:10.1515/revneuro.1998.9.1.1 · Cited by 30
Transgenic Animals in Alzheimer's Disease Research
Sturchler, C., & Sommer, B. (1999) · Reviews in the Neurosciences · doi:10.1515/revneuro.1999.10.1.15 · Cited by 33
Different effects of Alzheimer-associated mutations of presenilin 1 on its processing
Murayama, O., Honda, T., Mercken, M. H., Murayama, M., Yasutake, K., Nihonmatsu, N., Nakazato, Y., Michel, G., Song, S., Sato, K., et al. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00417-5 · Cited by 29
Probing Mechanisms and Therapeutic Potential of γ-Secretase in Alzheimer’s Disease
Wolfe, M. S. (2021) · Molecules · doi:10.3390/molecules26020388 · Cited by 28
Mouse Models of Alzheimer’s Dementia: Current Concepts and New Trends
Torres‐Alemán, I. (2008) · Endocrinology · doi:10.1210/en.2008-0905 · Cited by 32
“better suited for experimental studies (20).”
Mutant presenilin (A260V) affects Rab8 in PC12D cell
Kametani, F., Usami, M., Tanaka, K., Kume, H., & Mori, H. (2003) · Neurochemistry International · doi:10.1016/s0197-0186(03)00176-1 · Cited by 29
Role of microbial dysbiosis in the pathogenesis of Alzheimer's disease
Susmitha, G., & Kumar, R. K. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109478 · Cited by 28
Giudice, E. D., Facchinetti, F., Nofrate, V., Boccaccio, P., Minelli, T. A., Dam, M., Leon, A., & Moschini, G. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.02.057 · Cited by 27
Chiba, T., Nishimoto, I., Aiso, S., & Matsuoka, M. (2007) · Molecular Neurobiology · doi:10.1007/bf02700624 · Cited by 31
Takami, M., & Funamoto, S. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/591392 · Cited by 27
No post-genetics era in human disease research
Gusella, J. F., & MacDonald, M. E. (2002) · Nature Reviews Genetics · doi:10.1038/nrg706 · Cited by 27
“Many different approaches have been used to manipulate the genes that are implicated in AD to produce a phenotypic mouse model, including transgenic expression of the Aβ peptide, overexpression of wild-type and mutant human APPs , overexpression of mutant presenilins and a mouse knock-in of a presenilin mutatio”
MethodRelkin, N. R. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.6.735 · Cited by 28
Gong, P., Vetrivel, K. S., Nguyen, P. D., Meckler, X., Cheng, H., Kounnas, M. Z., Wagner, S. L., Parent, A., & Thinakaran, G. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.132613 · Cited by 27
Effect of Ischemic Neuronal Insults on Amyloid Precursor Protein Processing
Lee, P. H., Hwang, E. M., Hong, H., Boo, J. H., Mook‐Jung, I., & Huh, K. (2006) · Neurochemical Research · doi:10.1007/s11064-006-9086-y · Cited by 30
“가한다는 사실은 presenilin이 Aβ의 생성에 중요한 역할을 한 다는 것을 제시한다.(38,39) Presenilin은 8개의 transmembrane 부분을 갖는 단백질이며,(40,41) endoplasmic reticulum과 Golgi 에 주로 존재하고 소량은 세포 표면에 존재하며, 기존의 연구에 의하면 presenilin은 그 자체가 type1 transmembrane 단백질 을 자르는 γ-secretase로서 기능하거나 혹은 다른 단백질과 복 합체를 형성하여 γ-secretase 활성에 중요한 역할을 하는 단백 질이다.”
Dowjat, W. K., Kuchna, I., Wısnıewskı, T., & Węgiel, J. (2004) · Journal of Alzheimer s Disease · doi:10.3233/jad-2004-6105 · Cited by 27
“Therefore, the magnitude of this effect does not appear to be a distinctive feature of Pro117 mutations and, similar to other FAD mutations [4,22,28], does not correlate with the age at onset or severity of disease.”
BackgroundResultInfluentialArtificial gravity as a countermeasure in long-duration space flight
Lackner, J. R., & DiZio, P. A. (2000) · Journal of Neuroscience Research · doi:10.1002/1097-4547(20001015)62:2<169::aid-jnr2>3.0.co;2-b · Cited by 42
Presenilin Function in APP Processing
Annaert, W. G., Cupers, P., Säftig, P., & Strooper, B. D. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06917.x · Cited by 33
Transgenic mouse models of Alzheimer's disease: phenotype and mechanisms of pathogenesis
Duff, K. (2001) · Biochemical Society Symposia · doi:10.1042/bss0670195 · Cited by 26
Shirotani, K., Takahashi, K., Araki, W., Maruyama, K., & Tabira, T. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.5.3681 · Cited by 27
Lévesque, L., Annaert, W., Craessaerts, K., Mathews, P. M., Seeger, M., Nixon, R. A., Van Leuven, F., Gandy, S., Westaway, D., St George-Hyslop, P., et al. (1999) · Molecular Medicine · doi:10.1007/bf03401981 · Cited by 21
Self-citationAmritraj, A., Hawkes, C. A., Phinney, A. L., Mount, H. T. J., Scott, C. D., Westaway, D. A., & Kar, S. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.05.004 · Cited by 28
Self-citationKrezowski, J., Knudson, D., Ebeling, C., Pitstick, R., Giri, R. K., Schenk, D., Westaway, D., Younkin, L., Younkin, S. G., Ashe, K. H., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh210 · Cited by 30
Kurata, T., Kawarabayashi, T., Murakami, T., Miyazaki, K., Morimoto, N., Ohta, Y., Takehisa, Y., Nagai, M., Ikeda, M., Matsubara, E., et al. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21352 · Cited by 26
“The generation of transgenic lines overexpressing FAD PS-1 L286V (PS1L286Vtg: 198) is described elsewhere (Citron et al., 1997).”
BackgroundSelf-citationMurayama, O., Murayama, M., Honda, T., Sun, X., Nihonmatsu, N., & Takashima, A. (1999) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(99)00034-2 · Cited by 26
Immunoreactivity of Presenilin-1 and Tau in Alzheimer's Disease Brain
Hendriks, L., Jonghe, C. D., Lübke, U., Woodrow, S., Vanderhoeven, I., Boons, J., Cras, P. P., Martin, J., & Broeckhoven, C. V. (1998) · Experimental Neurology · doi:10.1006/exnr.1997.6739 · Cited by 26
Tamaoka, A., Fraser, P. E., Ishii, K., Sahara, N., Ozawa, K., Ikeda, M., Saunders, A. M., Komatsuzaki, Y., Sherrington, R., Lévesque, G., et al. (1998) · Molecular Brain Research · doi:10.1016/s0169-328x(98)00044-8 · Cited by 30
Self-citationAlzheimer transgenic mouse models come of age
Duff, K. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(97)01093-x · Cited by 26
Thornton‐Wells, T. A., Moore, J. H., Martin, E. R., Pericak‐Vance, M. A., & Haines, J. L. (2007) · Genetic Epidemiology · doi:10.1002/gepi.20294 · Cited by 26
5-HT4 Receptor Stimulation Leads to Soluble AβPPα Production Through MMP-9 Upregulation
Hashimoto, G., Sakurai, M., Teich, A. F., Saeed, F., Aziz, F., & Arancio, O. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-111235 · Cited by 27
Marambaud, P., Ancolio, K., da Costa, C. A., & Checler, F. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702406 · Cited by 25
Binding Mechanism of Inositol Stereoisomers to Monomers and Aggregates of Aβ(16-22)
Li, G., & Pomès, R. (2013) · The Journal of Physical Chemistry B · doi:10.1021/jp311350r · Cited by 25
Morelli, L., Llovera, R. E., Ibendahl, S., & Castaño, E. M. (2002) · Neurochemical Research · doi:10.1023/a:1021679817756 · Cited by 27
“tosomal dominant forms of AD increase the steadystate ratio of Ab42–43/Ab40 in cultured cells and brains of transgenic mice carrying such mutants, (19,20) and (iv) Ab42–43 is highly toxic for neurons in culture either in fibrillar or non-fibrillar oligomeric forms (reviewed in 41).”
BackgroundDistinguishable effects of Presenilin-1 and APP717 mutations on amyloid plaque deposition
Ishii, K., Lippa, C. F., Tomiyama, T., Miyatake, F., Ozawa, K., Tamaoka, A., Hasegawa, T., Fraser, P. E., Shoji, S., Nee, L. E., et al. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00216-0 · Cited by 25
Self-citationMolecular Genetics of Alzheimer's Disease
Verdile, G., & Martin, R. (2008) · Nucleic acids and molecular biology · doi:10.1007/978-3-540-85383-1_8 · Cited by 26
Presenilin-1 is associated with Alzheimer's disease amyloid.
Wısnıewskı, T., Dowjat, W. K., Permanne, B., Palha, J. A., Kumar, A., Gallo, G., & Frangione, B. (1997) · Europe PMC (PubMed Central) · Cited by 25
Monogenic determinants of familial Alzheimer's disease: presenilin-2 mutations
Renbaum, P., & Levy‐Lahad, E. (1998) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050220 · Cited by 25
Studies on the first described Alzheimer's disease amyloid β mutant, the Dutch variant
Levy, E., Prelli, F., & Frangione, B. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9s337 · Cited by 24
An Alternative View of Familial Alzheimer’s Disease Genetics
Lardelli, M. T. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230313 · Cited by 24
“A 2023 study (Liu et al. [100]) examined the production of A (cid:2) fragments with lengths of 37, 38, 39, 40, 42, and 43 as produced by HEK293 cells lacking endogenous presenilin s but transfected to express wild type, or one of 130 different fAD mutant forms, of PSEN1 (together with A (cid:2)…”
Honarnejad, K., Daschner, A., Gehring, A. P., Szybińska, A., Giese, A., Kuźnicki, J., Bracher, F., & Herms, J. W. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.132 · Cited by 24
Akatsu, H., Ogawa, N., Kanesaka, T., Hori, A., Yamamoto, T., Matsukawa, N., & Michikawa, M. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2010.09.030 · Cited by 26
“Mutations in the amyloid precursor protein (APP), presenilin 1 (PS1), PS2 genes were found in the majority of pedigreed cases of early-onset FAD [2,3]; these mutations were reported to lead to abnormal Aβ cleavage and deposition [4].”
BackgroundPathogenesis of Alzheimer’s Disease
Castellani, R. J., Plascencia‐Villa, G., & Perry, G. L. (2022) · Springer eBooks · doi:10.1007/978-3-031-15080-7_162 · Cited by 24
Potential novel targets for Alzheimer pharmacotherapy: I. Secretases
Maiorini, A. F., Gaunt, M., Jacobsen, T., McKay, A. E., Waldman, L., & Raffa, R. B. (2002) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2002.00415.x · Cited by 26
“A caveat is that there does not appear to be a correlation between high levels of c-secretase activity and high levels of presenilins (88).”
BackgroundDecreased Aβ secretion by cells expressing familial Alzheimer's disease-linked mutant presenilin 1
Shimojo, M., Sahara, N., Murayama, M., Ichinose, H., & Takashima, A. (2007) · Neuroscience Research · doi:10.1016/j.neures.2006.12.005 · Cited by 33
Taylor-Walker, G., Lynn, S. A., Keeling, E., Munday, R., Johnston, D. A., Page, A. M., Scott, J. A., Goverdhan, S., Lotery, A. J., & Ratnayaka, J. A. (2016) · Experimental Eye Research · doi:10.1016/j.exer.2016.10.013 · Cited by 24
Presenilin-1 mutation E318G and familial Alzheimer's disease in the Italian population
Albani, D., Roiter, I., Artuso, V., Batelli, S., Prato, F., Pesaresi, M., Galimberti, D., Scarpini, E. A., Bruni, A. C., Franceschi, M., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.07.003 · Cited by 24
Honda, T., Nihonmatsu, N., Yasutake, K., Ohtake, A., Sato, K., Tanaka, S., Murayama, O., Murayama, M., & Takashima, A. (2000) · Neuroscience Research · doi:10.1016/s0168-0102(00)00106-1 · Cited by 24
“…increase the level of the secreted b-amyloid peptide terminating at amino acid 42 (Ab42) in cultured cells and transgenic mice (Martins et al., 1995; Borchelt et al., 1996; Duff et al., 1996; Lemere et al., 1996; Scheuner et al., 1996; Citron et al., 1997; Tomita et al., 1997; Xia et al., 1997).”
BackgroundMyers, A., Marshall, H. N., Holmans, P., Compton, D., Crook, R., Mander, A., Nowotny, P., Smemo, S., Dunstan, M. L., Jehu, L., et al. (2003) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.20036 · Cited by 24
“While the known mutations for the rare familial forms of AD produce more Ab by increasing either b- or g-cleavage of APP [Citron et al., 1992, 1997; Hsiao et al., 1996; Scheuner et al., 1996], APOE, the only known risk factor for LOAD, appears to act by affecting the deposition of fibrillar forms…”
BackgroundAβ43 aggregates exhibit enhanced prion-like seeding activity in mice
Ruiz‐Riquelme, A., Mao, A., Barghash, M. M., Lau, H. H. C., Stuart, E., Kovács, G. G., Nilsson, K. P. R., Fraser, P. E., Schmitt‐Ulms, G., & Watts, J. C. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01187-6 · Cited by 25
“To date, a majority of studies have focused on the two most abundant variants of Aβ, Aβ40 and Aβ42, with the evidence pointing to Aβ42 as the key mediator of AD pathogenesis since it is more prone to aggregate into neurotoxic species [29, 42] and its levels are selectively increased by AD-causing mutations in the pres…”
BackgroundSelf-citationMalter, J. S. (2022) · Translational research · doi:10.1016/j.trsl.2022.09.003 · Cited by 25
Zhang, J., Jiang, Y., Dong, X., Meng, Z., Ji, L., Kang, Y., Liu, M., Zhou, W., & Song, W. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01527-3 · Cited by 23
del Campo, M., & Teunissen, C. E. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131364 · Cited by 27
Biomarkers, ketone bodies, and the prevention of Alzheimer’s disease
VanItallie, T. B. (2014) · Metabolism · doi:10.1016/j.metabol.2014.10.033 · Cited by 25
“In ASD angiopathy, mutations in each of these proteins may be responsible for shifting APP processing toward the formation of Aβ42, thereby promoting cerebral β-amyloidosis [34].”
BackgroundKimpe, L. D., & Scheper, W. (2009) · Current Medicinal Chemistry · doi:10.2174/092986710790149765 · Cited by 26
“All these mutations can directly be linked to altered or increased A formation [3-7].”
BackgroundSatoh, & Kuroda (1999) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.1999.00209.x · Cited by 23
Cardoso, B. R., Ong, T. P., Filho, W. J., Jaluul, O., Freitas, M. I. D., Cominetti, C., & Cozzolino, S. M. F. (2012) · Lifestyle Genomics · doi:10.1159/000338682 · Cited by 23
Presenilin‐1‐mediated Retention of APP Derivatives in Early Biosynthetic Compartments
Réchards, M., Xia, W., Oorschot, V. M. J., van Dijk, S., Annaert, W. G., Selkoe, D. J., & Klumperman, J. (2006) · Traffic · doi:10.1111/j.1600-0854.2006.00388.x · Cited by 23
Self-citationVestling, M., Cedazo-Mínguez, Á., Adem, A., Wiehager, B., Racchi, M., Lannfelt, L., & Cowburn, R. F. (1999) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(99)00003-4 · Cited by 23
Metadata
- Authors
- Citron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., Johnson-wood, K., Lee, M., Seubert, P., Davis, A., Kholodenko, D., Motter, R., Sherrington, R., Perry, B., Yao, H., Strome, R., Lieberburg, I., Rommens, J., Kim, S., Schenk, D., Fraser, P., St George Hyslop, P., & Selkoe, D. J.
- Affiliations
- Brigham and Women's Hospital (US)
- University of Toronto (CA)
- McLaughlin Research Institute (US)
- Harvard University (US)
- ORCID
- Venue
- Nature Medicine
- Published
- 1997-01
- Volume
- 3
- Issue
- 1
- Pages
- 67-72
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2081998222
- Cited by
- 1,271
- References
- 28
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 15 · 2023: 20 · 2022: 18 · 2021: 26 · 2020: 29 · 2019: 28 · 2018: 20 · 2017: 20 · 2016: 32 · 2015: 35 · 2014: 38 · 2013: 33 · 2012: 49
- FWCI
- 68.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (64309)
- National Institute on Aging (AG 12749, AG-06173, AG 106812, R01AG012749)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- presenilin mutations, Alzheimer's disease, amyloid-beta 42, presenilin 1, presenilin 2, gain-of-function mutations, transgenic mouse model, beta-amyloidosis, early-onset Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Animals, Brain, Cell Line, Enzyme-Linked Immunosorbent Assay, Genetic Vectors, Hippocampus, Humans, Membrane Proteins, Mice, Transgenic, Mutation, Peptide Fragments, Transfection, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Mice, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.